Rising Geriatric Population To Drive The Market Growth Is Supporting Development Across The Dry Age Related Macular Degeneration (AMD) Market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Size Of The Dry Age Related Macular Degeneration (AMD) Market Progress Through 2030?
The market for dry age-related macular degeneration (amd) has experienced substantial growth in recent years. It is anticipated to expand from $4.89 billion in 2025 to $5.32 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.8%. This historical growth can be attributed to factors such as the increasing aging population, the expansion of ophthalmology clinics, the adoption of vitamin-based therapies, advancements in retinal imaging, and greater awareness of vision loss.
The dry age related macular degeneration (amd) market size is projected to experience robust expansion over the upcoming years. This market is set to reach $7.36 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. The expansion during the forecast period is propelled by factors such as the development of new therapeutic pipelines, advancements in precision ophthalmology, the emergence of AI-based retinal diagnostics, various preventive eye care initiatives, and significant investments in clinical trials. Key developments anticipated during this timeframe involve a heightened emphasis on detecting the disease early, a greater reliance on nutritional supplement treatments, expanded research into drugs that modify the disease, an increasing embrace of sophisticated retinal imaging techniques, and improved patient understanding and screening efforts.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21176&type=smp
Which Growth Drivers Are Expected To Support The Dry Age Related Macular Degeneration (AMD) Market Forward?
The dry age-related macular degeneration (AMD) market is anticipated to experience growth, primarily propelled by the increasing geriatric population. This demographic specifically refers to individuals aged 65 years and older who, due to age-related physiological changes, have an elevated need for healthcare and vision-care services. Globally, the rise in the geriatric population is attributable to factors like extended life expectancy, better management of chronic diseases, advancements in medical technology, and wider access to specialized care for the elderly. The dry age-related macular degeneration (AMD) market addresses this need by offering targeted therapies and management solutions designed to slow retinal degeneration and preserve vision in older adults. A notable illustration, according to the United Nations, a US-based intergovernmental organization, in July 2023, indicated that the global population aged 65 years and older stood at 0.77 billion in 2022 and is forecasted to reach approximately 1.0 billion by 2030. Thus, the expanding elderly demographic is a significant driver for the growth of the dry age-related macular degeneration (AMD) market.
What Are The Major Segment Categories Within The Dry Age Related Macular Degeneration (AMD) Market?
The dry age related macular degeneration (amd) market covered in this report is segmented –
1) By Stages: Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years, Above 60 Years, Above 40 Years
3) By Route Of Administration: Oral, Injectables
4) By End Users: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes
Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation, Retinal Pigment Epithelium Changes
2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits, Increased Pigmentary Abnormalities
3) By Late Age-Related Macular Degeneration: Geographic Atrophy, Central Vision Loss
What Trends Are Influencing The Future Of The Dry Age Related Macular Degeneration (AMD) Market?
Leading companies in the dry age-related macular degeneration (AMD) market are concentrating on developing sophisticated technologies, such as light delivery systems, to stimulate retinal cells, enhance visual function, and potentially slow the advancement of the disease. Light delivery systems are defined as therapeutic instruments crafted to direct specific wavelengths of light to targeted retinal tissues, thereby boosting cellular activity and supporting retinal health through non-invasive photobiomodulation methods. For example, in January 2024, LumiThera Inc., a US-based medical device company, launched its photobiomodulation therapy for dry AMD utilizing the Valeda Light Delivery System, which is the inaugural FDA-authorized treatment for vision loss associated with dry AMD. The system employs a multi-wavelength light delivery approach, incorporating 590 nm, 660 nm, and 850 nm wavelengths to stimulate retinal cells, and LumiThera has commenced the EUROLIGHT registry study to gather long-term outcome data, with treatments typically administered across nine sessions over a period of three to four weeks.
Which Organizations Are Involved In The Dry Age Related Macular Degeneration (AMD) Market?
Major companies operating in the dry age related macular degeneration (amd) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Apellis Pharmaceuticals Inc., Belite Bio Inc., Alkeus Pharmaceuticals Inc., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc., Regeneron Pharmaceuticals Inc., Annexon Biosciences Inc., Stealth BioTherapeutics Corp., Kodiak Sciences Inc., Ionis Pharmaceuticals Inc., Lineage Cell Therapeutics Inc., Ocular Therapeutix Inc.
Access The Complete Dry Age Related Macular Degeneration (AMD) Market Report:
Which Region Commands The Largest Share Of The Dry Age Related Macular Degeneration (AMD) Market?
North America was the largest region in the dry age-related macular degeneration (AMD) market in 2025. The regions covered in the dry age related macular degeneration (amd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Dry Age Related Macular Degeneration (AMD) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21176&type=smp
Browse Through More Reports Similar to the Global Dry Age Related Macular Degeneration (AMD) Market 2026, By The Business Research Company
Macular Degeneration Treatment Global Market Report 2026
Macular Edema And Macular Degeneration Global Market Report 2026
Non Proliferative Diabetic Retinopathy Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
